Episode 523 - Rodolfo Estrada, MD
I'm Aware That I'm Rare: the phaware® podcast
Release Date: 06/03/2025
I'm Aware That I'm Rare: the phaware® podcast
Dr. Tijana Milinic and Lia Barros, DNP, from the University of Washington take a deep dive into the world of pulmonary arterial hypertension (PAH) clinical trials and discuss why diversity and inclusion matter. They explore the hidden biases in medical research and the real-world consequences of exclusion. Lia Barros, DNP: My name is Lia Barros and I'm a pulmonary vascular disease nurse practitioner specialist. I work at the University of Washington, where I've been practicing as a pulmonary vascular disease specialist for about the last four years. I was born and raised in this area. I'm...
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Dr. Tijana Milinic and Lia Barros, DNP, from the University of Washington take a deep dive into the world of pulmonary arterial hypertension (PAH) clinical trials and discuss why diversity and inclusion matter. They explore the hidden biases in medical research and the real-world consequences of exclusion. Learn more about pulmonary hypertension trials at . Engage for a cure: #phaware Share your story: Like, Subscribe and Follow us: . #phawareMD
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Dr. Lana Melendres-Groves dives into her research on racial and ethnic disparities in PAH treatment. From differences in medication access to the role of social determinants of health, she explores how systemic barriers impact care and what steps can be taken to ensure equity and inclusivity in PAH management. Hi, I am Lana Melendres-Groves. I'm at the University of New Mexico. I’m the Pulmonary Hypertension Medical Director of our Comprehensive Care Center. Today, I hope to dive into a little bit of the information that we have regarding how we care for different subgroups of our patients...
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Dr. Lana Melendres-Groves dives into her research on racial and ethnic disparities in PAH treatment. From differences in medication access to the role of social determinants of health, she explores how systemic barriers impact care and what steps can be taken to ensure equity and inclusivity in PAH management. Learn more about pulmonary hypertension trials at . Engage for a cure: #phaware Share your story: Like, Subscribe and Follow us: . #phawareMD
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Dr. Roham Zamanian, discusses the concept of "disease modification" in the treatment of pulmonary hypertension. He describes how this idea emerged from discussions with colleagues about the future of pulmonary hypertension therapies, and the potential for treatments to impact the underlying disease process beyond just reducing pulmonary artery pressures. This Special Edition Episode Sponsored by: My name is Roham Zamanian, and I'm the Medical Director of the Adult Pulmonary Hypertension Program at Stanford. Today, I want to talk about disease modification, something that historically,...
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Dr. Roham Zamanian, discusses the concept of "disease modification" in the treatment of pulmonary hypertension. He describes how this idea emerged from discussions with colleagues about the future of pulmonary hypertension therapies, and the potential for treatments to impact the underlying disease process beyond just reducing pulmonary artery pressures. This Special Edition Episode Sponsored by: Learn more about pulmonary hypertension trials at . Follow us on social @phaware Engage for a cure: #phaware Share your story: #phawareMD
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Hall Skaara, representing PHA Europe, brought to the forefront at the World Symposium on Pulmonary Hypertension, joining other members of Task Force 1. PHA Europe was well-represented with delegates including Eva Otter, Monika Tschida, Natalia Maeva, Tadeja Ravnik, and Nina Kobler. This prestigious event gathered over 1,500 of the brightest minds in the field of pulmonary hypertension, offering a unique opportunity for patients and professionals to collaborate and share insights, as well as for patient associations to network. This Special Edition Episode Sponsored by: My name is Hall...
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Hall Skaara, representing PHA Europe, brought to the forefront at the World Symposium on Pulmonary Hypertension, joining other members of Task Force 1. PHA Europe was well-represented with delegates including Eva Otter, Monika Tschida, Natalia Maeva, Tadeja Ravnik, and Nina Kobler. This prestigious event gathered over 1,500 of the brightest minds in the field of pulmonary hypertension, offering a unique opportunity for patients and professionals to collaborate and share insights, as well as for patient associations to network. This Special Edition Episode Sponsored by: Learn more...
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Why Pulmonary Hypertension Isn’t Just a Lung ProblemCardiologist Dr. Lisa Mielniczuk from the Mayo Clinic pulls back the curtain on one of the most common — yet misunderstood — forms of pulmonary hypertension: the kind caused by left heart disease. In this episode, she explains why it’s time we stop thinking of PH as a rare condition. My name's Lisa Mielniczuk. I'm a cardiologist and I work at the Mayo Clinic in Rochester, Minnesota. I've been working in the field of PH now for almost 20 years. I also work in the field of advanced heart failure and heart transplantation. I've...
info_outlineI'm Aware That I'm Rare: the phaware® podcast
Why Pulmonary Hypertension Isn’t Just a Lung ProblemCardiologist Dr. Lisa Mielniczuk from the Mayo Clinic pulls back the curtain on one of the most common — yet misunderstood — forms of pulmonary hypertension: the kind caused by left heart disease. In this episode, she explains why it’s time we stop thinking of PH as a rare condition. Learn more about pulmonary hypertension trials at . Follow us on social @phaware Engage for a cure: #phaware Share your story: #phawareMD
info_outline Dr. Rodolfo Estrada, is a seasoned pulmonologists currently at UT Health San Antonio with significant experience in the management of patients with different forms of pulmonary hypertension. In this episode, Dr. Estrada will discuss the technology and clinical development behind YUTREPIA™ (treprostinil) inhalation powder and why it might be a good option for some PAH and PH-ILD patients.
This Special Edition episode is sponsored by Liquidia.
Please see the Important Safety Information following this podcast. The Prescribing Information and Instructions for Use for YUTREPIA (treprostinil) inhalation powder are available at YUTREPIA.com.
YUTREPIA is approved for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.
Please see the Important Safety Information in the show notes. The Prescribing Information and Instructions for Use for YUTREPIA are available at YUTREPIA.com. Learn more about the INSPIRE study.
Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: [email protected] Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @Liquidia_Corp @REstradaMD @UTHealthSA
IMPORTANT SAFETY INFORMATION
Before you take YUTREPIA, tell your healthcare provider about all of your medical conditions, including if you:
- Have low blood pressure
- Have or have had bleeding problems
- Have asthma or chronic obstructive pulmonary disease (COPD)
- Are pregnant or plan to become pregnant. It is not known if this product will harm your unborn baby
- Are breastfeeding or plan to breastfeed. It is not known if this product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. YUTREPIA and other medicines may affect each other.
Especially tell your healthcare provider if you take:
- Medicines used to treat high blood pressure or heart disease
- Medicines that decrease blood clotting (anticoagulants)
- Water pills (diuretics)
- Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®)
What are the possible side effects of YUTREPIA?
This product can cause serious side effects, including:
- Low blood pressure (symptomatic hypotension). If you have low blood pressure, this product may lower your blood pressure more.
- Bleeding problems. This product may increase the risk of bleeding, especially in people who take blood thinners (anticoagulants).
The most common side effects of YUTREPIA are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking YUTREPIA because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing.
You may report side effects to the FDA at www.fda.gov/MedWatch or call 1–800-FDA-1088.
The risk information provided here is not comprehensive. To learn more about YUTREPIA, talk with your healthcare provider. Please see Full Prescribing Information for YUTREPIA and Instructions for Use. For additional information, call 1–888–393–5732.